Sirtuins: exploring next-gen therapeutics in the pathogenesis osteoporosis and associated diseases

References

• Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study group. Osteoporos Int. 1994;4(6):368–381. doi:10.1007/BF01622200.
   PubMed Web of Science ®Google Scholar
• Yoo JH, Moon SH, Ha YC, et al. Osteoporotic fracture: 2015 position statement of the Korean Society for Bone and Mineral Research. J Bone Metab. 2015;22(4):175–181. doi:10.11005/jbm.2015.22.4.1758.
   PubMedGoogle Scholar
• Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S131–S139. doi:10.2215/CJN.041512068.
   PubMed Web of Science ®Google Scholar
• Cooper C, Campion G, Melton LJ.3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285–289. doi:10.1007/BF01623184.
   PubMed Web of Science ®Google Scholar
• Randell A, Sambrook PN, Nguyen TV, et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int. 1995;5(6):427–432. doi:10.1007/BF01626603.
   PubMed Web of Science ®Google Scholar
• Melton LJ, 3rd, Chrischilles EA, Cooper C, et al. Perspective how many women have osteoporosis? J Bone Miner Res. 1992;7(9):1005–1010. doi:10.1002/jbmr.5650070902.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2 Suppl 1):S4–S9. doi:10.1016/j.bone.2005.11.0247.
   PubMed Web of Science ®Google Scholar
• Guglielmi G. Osteoporosis and bone densitometry measurements. Berlin: Springer; 2013.
   Google Scholar
• Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–2526. doi:10.1002/jbmr.22692.
   PubMed Web of Science ®Google Scholar
• Hagino H, Furukawa K, Fujiwara S, et al. Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan. Osteoporos Int. 2009;20(4):543–548. doi:10.1007/s00198-008-0685-07.
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. doi:10.1007/s00198-014-2794-28.
   PubMed Web of Science ®Google Scholar
• Kanis JA. Assessment of osteoporosis at the primary health-care level. Tech Rep. 2007;12(4):390–406.
   Google Scholar
• Li Q, Cheng JC-Y, Jiang Q, et al. Role of sirtuins in bone biology: potential implications for novel therapeutic strategies for osteoporosis. Aging Cell. 2021;20(2):e13301. doi:10.1111/acel.133015.
   PubMed Web of Science ®Google Scholar
• Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44(3):497–515. doi:10.1016/j.ecl.2015.05.0019.
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Bruyere O, Cannata-Andia JB, et al. Management of osteoporosis in the elderly. Curr Med Res Opin. 2009;25(10):2373–2387. doi:10.1185/030079909031692621.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Morin SN. Osteoporosis epidemiology 2013: implications for diagnosis, risk assessment, and treatment. Curr Opin Rheumatol. 2014;26(4):440–446. doi:10.1097/BOR.00000000000000642.
   PubMed Web of Science ®Google Scholar
• Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and management of osteoporosis. Am Fam Physician. 2015;92(4):261–268.1.
   PubMed Web of Science ®Google Scholar
• Tu KN, Lie JD, Wan CK, et al. Osteoporosis: a review of treatment options. P T. 2018;43(2):92–104.6
   PubMedGoogle Scholar
• North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American menopause society. Menopause. 2006;13(3):340–369. doi:10.1097/01.gme.0000222475.93345.b3.1.
   PubMed Web of Science ®Google Scholar
• Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115(12):3318–3325. doi:10.1172/JCI270715.
   PubMed Web of Science ®Google Scholar
• Kawamata A, Iihara M, Okamoto T, et al. Bone mineral density before and after surgical cure of Cushing’s syndrome due to adrenocortical adenoma: prospective study. World J Surg. 2008;32(5):890–896. doi:10.1007/s00268-007-9394-72.
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537. doi:10.1002/art.401373.
   PubMed Web of Science ®Google Scholar
• Ro C, Cooper O. Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep. 2013;11(1):45–51. doi:10.1007/s11914-012-0129-9.5.
   PubMed Web of Science ®Google Scholar
• Lin JT, Lane JM. Osteoporosis: a review. Clin Orthop Relat Res. 2004;425(425):126–134.7.
   Google Scholar
• Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423(6937):349–355. 15doi: 10.1038/nature016604.
   PubMed Web of Science ®Google Scholar
• Li X, Wang L, Huang B, et al. Targeting actin-bundling protein L-plastin as an anabolic therapy for bone loss. Sci Adv. 2020;6(47):eabb7135. doi:10.1126/sciadv.abb71358.
   PubMed Web of Science ®Google Scholar
• Shanks G, Sharma D, Mishra V. Prevention and treatment of osteoporosis in women. Obstet Gynaecol Reprod Med. 2019;29(7):201–206. doi:10.1016/j.ogrm.2019.04.001.
   Google Scholar
• Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol. 2007;72(1):483–488. doi:10.1101/sqb.2007.72.0248.
   PubMedGoogle Scholar
• Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010;5(1):253–295. doi:10.1146/annurev.pathol.4.110807.0922501.
   PubMedGoogle Scholar
• Nakagawa T, Guarente L. SnapShot: sirtuins, NAD, and aging. Cell Metab. 2014;20(1):192–192.e1. doi:10.1016/j.cmet.2014.06.0018.
   PubMedGoogle Scholar
• Choudhary C, Weinert BT, Nishida Y, et al. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol. 2014;15(8):536–550. doi:10.1038/nrm38419.
   PubMed Web of Science ®Google Scholar
• Wagner GR, Hirschey MD. Nonenzymatic protein acylation as a carbon stress regulated by sirtuin deacylases. Mol Cell. 2014;54(1):5–16. doi:10.1016/j.molcel.2014.03.0274.
   PubMed Web of Science ®Google Scholar
• Haigis MC, Guarente LP. Mammalian sirtuins–emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006;20(21):2913–2921. doi:10.1101/gad.14675062.
   PubMed Web of Science ®Google Scholar
• Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD + and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016;17(11):679–690. doi:10.1038/nrm.2016.931.
   PubMed Web of Science ®Google Scholar
• Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–196. 11 doi: 10.1038/nature019607.
   PubMed Web of Science ®Google Scholar
• Kane AE, Sinclair DA. Sirtuins and NAD + in the development and treatment of metabolic and cardiovascular diseases. Circ Res. 2018;123(7):868–885. doi:10.1161/CIRCRESAHA.118.3124982.
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506. doi:10.1038/nrd20600.
   PubMed Web of Science ®Google Scholar
• Baur JA, Ungvari Z, Minor RK, et al. Sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012;11(6):443–461. doi:10.1038/nrd37386.
   PubMed Web of Science ®Google Scholar
• Novelle MG, Wahl D, Diéguez C, et al. Resveratrol supplementation: where are we now and where should we go? Ageing Res Rev. 2015;21:1–15. doi:10.1016/j.arr.2015.01.0021.
   PubMed Web of Science ®Google Scholar
• Kulkarni SS, Cantó C. The molecular targets of resveratrol. Biochim Biophys Acta. 2015;1852(6):1114–1123. doi:10.1016/j.bbadis.2014.10.005.
   PubMed Web of Science ®Google Scholar
• Knight CM, Gutierrez-Juarez R, Lam TK, et al. Mediobasal hypothalamic SIRT1 is essential for resveratrol’s effects on insulin action in rats. Diabetes. 2011;66(12):3143–3144. doi:10.2337/db10-09878.
   Google Scholar
• Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5):675–690. doi:10.1016/j.cmet.2012.04.0030.
   PubMed Web of Science ®Google Scholar
• Zhao M, Ko SY, Garrett IR, et al. The polyphenol resveratrol promotes skeletal growth in mice through a sirtuin 1-bone morphogenic protein 2 longevity axis. Br J Pharmacol. 2018;175(21):4183–4192. doi:10.1111/bph.144773.
   PubMed Web of Science ®Google Scholar
• Stegen S, Stockmans I, Moermans K, et al. Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin. Nat Comm. 2018;9(1):2557.
   PubMedGoogle Scholar
• Bäckesjö CM, Li Y, Lindgren U, et al. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res. 2006;21(7):993–1002. doi:10.1359/jbmr.0604150.
   PubMed Web of Science ®Google Scholar
• Zhou H, Shang L, Li X, et al. Removal notice to "resveratrol augments the canonical wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells". Exp Cell Res. 2021;404(1):112609. doi:10.1016/j.yexcr.2021.1126095.
   PubMed Web of Science ®Google Scholar
• Shakibaei M, Buhrmann C, Mobasheri A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem. 2011;286(13):11492–11505. doi:10.1074/jbc.M110.1987132.
   PubMed Web of Science ®Google Scholar
• Kim HN, Han L, Iyer S, et al. Sirtuin1 suppresses osteoclastogenesis by deacetylating FoxOs. Mol Endocrinol. 2015;29(10):1498–1509. doi:10.1210/me.2015-1133.
   PubMedGoogle Scholar
• He X, Andersson G, Lindgren U, et al. Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun. 2010;401(3):356–362. doi:10.1016/j.bbrc.2010.09.0537.
   PubMed Web of Science ®Google Scholar
• Gurt I, Artsi H, Cohen-Kfir E, et al. The Sirt1 activators SRT2183 and SRT3025 inhibit RANKL-induced osteoclastogenesis in bone marrow-derived macrophages and down-regulate Sirt3 in Sirt1 null cells. PLoS One. 2015;10(7):e0134391. doi:10.1371/journal.pone.01343914.
   PubMed Web of Science ®Google Scholar
• Almeida M, Porter RM. Sirtuins and FoxOs in osteoporosis and osteoarthritis. Bone. 2019;121:284–292. doi:10.1016/j.bone.2019.01.0184.
   PubMed Web of Science ®Google Scholar
• Zainabadi K, Liu CJ, Caldwell ALM, et al. SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. PLoS One. 2017;12(9):e0185236. doi:10.1371/journal.pone.01852366.
   PubMed Web of Science ®Google Scholar
• Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8(2):157–168. doi:10.1016/j.cmet.2008.06.0113.
   PubMed Web of Science ®Google Scholar
• Herranz D, Muñoz-Martin M, Cañamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1(1):3. doi:10.1038/ncomms10015.
   PubMedGoogle Scholar
• Momken I, Stevens L, Bergouignan A, et al. Resveratrol prevents the wasting disorders of mechanical unloading by acting as a physical exercise mimetic in the rat. FASEB J. 2011;25(10):3646–3660. doi:10.1096/fj.10-1772952.
   PubMed Web of Science ®Google Scholar
• Su JL, Yang CY, Zhao M, et al. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem. 2007;282(27):19385–19398. doi:10.1074/jbc.M7024522007.
   PubMed Web of Science ®Google Scholar
• Artsi H, Cohen-Kfir E, Gurt I, et al. The Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. Endocrinol. 2014;155(9):3508–3515. doi:10.1210/en.2014-13345.
   PubMed Web of Science ®Google Scholar
• Ornstrup MJ, Harsløf T, Kjær TN, et al. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2014;99(12):4720–4729. doi:10.1210/jc.2014-27994.
   PubMed Web of Science ®Google Scholar
• Zainabadi K. Drugs targeting SIRT1, a new generation of therapeutics for osteoporosis and other bone related disorders? Pharmacol Res. 2019;143:97–105. doi:10.1016/j.phrs.2019.03.0076.
   PubMed Web of Science ®Google Scholar
• Cheng HL, Mostoslavsky R, Saito SI, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A. 2003;100(19):10794–10799. doi:10.1073/pnas.1934713100.
   PubMed Web of Science ®Google Scholar
• Lemieux ME, Yang X, Jardine K, et al. The Sirt1 deacetylase modulates the insulin-like growth factor signaling pathway in mammals. Mech Aging Dev. 2005;126(10):097–105.
   Web of Science ®Google Scholar
• McBurney MW, Yang X, Jardine K, et al. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol. 2003;23(1):38–54. doi:10.1128/MCB.23.1.38-54.20039.
   PubMed Web of Science ®Google Scholar
• Mercken EM, Mitchell SJ, Martin-Montalvo A, et al. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell. 2014;13(5):787–796. doi:10.1111/acel.122205.
   PubMed Web of Science ®Google Scholar
• Cohen-Kfir E, Artsi H, Levin A, et al. Sirt1 is a regulator of bone mass and a repressor of sost encoding for sclerostin, a bone formation inhibitor. Endocrinol. 2011;152(12):4514–4524. doi:10.1210/en.2011-11285.
   PubMed Web of Science ®Google Scholar
• Kolthur-Seetharam U, Teerds K, de Rooij DG, et al. The histone deacetylase SIRT1 controls male fertility in mice through regulation of hypothalamic-pituitary gonadotropin signaling. Biol Reprod. 2009;80(2):384–391. doi:10.1095/biolreprod.108.0701933.
   PubMed Web of Science ®Google Scholar
• Toorie AM, Cyr NE, Steger JS, et al. The nutrient and energy sensor Sirt1 regulates the hypothalamic-pituitary-adrenal (HPA) axis by altering the production of the prohormone convertase 2 (PC2) essential in the maturation of corticotropin-releasing hormone (CRH) from its prohormone in male rats. J Biol Chem. 2016;291(11):5844–5859. doi:10.1074/jbc.M115.6752641.
   PubMed Web of Science ®Google Scholar
• Elbaz A, Rivas D, Duque G. Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontol. 2009;10(6):747–755. doi:10.1007/s10522-009-9221-75.
   PubMed Web of Science ®Google Scholar
• Shakibaei M, Shayan P, Busch F, et al. Resveratrol mediated modulation of sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. PLoS One. 2012;7(4):e35712. doi:10.1371/journal.pone.00357124.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen L, Peng W. Protective effects of resveratrol on osteoporosis via activation of the SIRT1-NF-κB signaling pathway in rats. Exp Ther Med. 2017;14(5):5032–5038. doi:10.3892/etm.2017.51470.
   PubMed Web of Science ®Google Scholar
• Edwards JR, Perrien DS, Fleming N, et al. Silent information regulator (sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. J Bone Miner Res. 2013;28(4):960–969. doi:10.1002/jbmr.18246.
   PubMed Web of Science ®Google Scholar
• Simic P, Zainabadi K, Bell E, et al. SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β‐catenin. EMBO Mol Med. 2013;5(3):430–440. doi:10.1002/emmm.201201606.
   PubMed Web of Science ®Google Scholar
• Iyer S, Han L, Bartell SM, et al. Sirtuin1 (Sirt1) promotes cortical bone formation by preventing β-catenin sequestration by FoxO transcription factors in osteoblast progenitors. J Biol Chem. 2014;289(35):24069–24078. doi:10.1074/jbc.M114.5618039.
   PubMed Web of Science ®Google Scholar
• Elangovan S, Ramachandran S, Venkatesan N, et al. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Res. 2011;71(21):6654–6664. doi:10.1158/0008-5472.CAN-11-14469.
   PubMed Web of Science ®Google Scholar
• Yu EJ, Kim SH, Heo K, et al. Reciprocal roles of DBC1 and SIRT1 in regulating estrogen receptor α activity and co-activator synergy. Nucleic Acids Res. 2011;39(16):6932–6943. doi:10.1093/nar/gkr3472.
   PubMed Web of Science ®Google Scholar
• Yoon DS, Choi Y, Jang Y, et al. SIRT1 directly regulates SOX2 to maintain self-renewal and multipotency in bone marrow-derived mesenchymal stem cells. Stem Cells. 2014;32(12):3219–3231. doi:10.1002/stem.18113.
   PubMed Web of Science ®Google Scholar
• Jin X, Kang X, Zhao L, et al. Cartilage ablation of Sirt1 causes inhibition of growth plate chondrogenesis by hyperactivation of mTORC1 signaling. Endocrinol. 2019;160(12):3001–3017. doi:10.1210/en.2019-004275.
   PubMed Web of Science ®Google Scholar
• Dvir-Ginzberg M, Gagarina V, Lee EJ, et al. Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem. 2008;283(52):36300–36310. doi:10.1074/jbc.M8031962007.
   PubMed Web of Science ®Google Scholar
• Hong EH, Lee SJ, Kim JS, et al. Ionizing radiation induces cellular senescence of articular chondrocytes via negative regulation of SIRT1 by p38 kinase. J Biol Chem. 2010;285(2):1283–1295. doi:10.1074/jbc.M109.0586282.
   PubMed Web of Science ®Google Scholar
• Fujita N, Matsushita T, Ishida K, et al. Potential involvement of SIRT1 in the pathogenesis of osteoarthritis through the modulation of chondrocyte gene expressions. J Orthop Res. 2011;29(4):511–515. doi:10.1002/jor.212840.
   PubMed Web of Science ®Google Scholar
• Takayama K, Ishida K, Matsushita T, et al. SIRT1 regulation of apoptosis of human chondrocytes. Arthritis Rheum. 2009;60(9):2731–2740. doi:10.1002/art.248640.
   PubMed Web of Science ®Google Scholar
• Matsuzaki T, Matsushita T, Takayama K, et al. Disruption of Sirt1 in chondrocytes causes accelerated progression of osteoarthritis under mechanical stress and during ageing in mice. Ann Rheum Dis. 2014;73(7):1397–1404. doi:10.1136/annrheumdis-2012-2026208.
   PubMed Web of Science ®Google Scholar
• Shtaif B, Bar-Maisels M, Gabet Y, et al. Cartilage -specific knockout of Sirt1 significantly reduces bone quality and catch-up growth efficiency. Bone. 2020;138:115468. doi:10.1016/j.bone.2020.1154683.
   PubMed Web of Science ®Google Scholar
• Sun W, Qiao W, Zhou B, et al. Overexpression of Sirt1 in mesenchymal stem cells protects against bone loss in mice by FOXO3a deacetylation and oxidative stress inhibition. Metabolism. 2018;88:61–71. doi:10.1016/j.metabol.2018.06.0060.
   PubMed Web of Science ®Google Scholar
• Wang H, Hu Z, Wu J, et al. Sirt1 promotes osteogenic differentiation and increases alveolar bone mass via Bmi1 activation in mice. J Bone Miner Res. 2019;34(6):1169–1181. doi:10.1002/jbmr.36778.
   PubMed Web of Science ®Google Scholar
• El-Haj M, Gurt I, Cohen-Kfir E, et al. Reduced Sirtuin1 expression at the femoral neck in women who sustained an osteoporotic hip fracture. Osteoporos Int. 2016;27(7):2373–2378. doi:10.1007/s00198-016-3536-43.
   PubMed Web of Science ®Google Scholar
• Abdelmohsen K, Pullmann R, Jr, Lal A, et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell. 2007;25(4):543–557. doi:10.1016/j.molcel.2007.01.0117.
   PubMed Web of Science ®Google Scholar
• Zhang J, Lazarenko OP, Kang J, et al. Feeding blueberry diets to young rats dose-dependently inhibits bone resorption through suppression of RANKL in stromal cells. PLoS On. 2013;8(8):e70438. doi:10.1371/journal.pone.00704381.
   Google Scholar
• Kumar R, Mohan N, Upadhyay AD, et al. Identification of serum sirtuins as novel noninvasive protein markers for frailty. Aging Cell. 2014;13(6):975–980. doi:10.1111/acel.122609.
   PubMed Web of Science ®Google Scholar
• Yang G, Hamadeh IS, Katz J, et al. SIRT1/HERC4 locus associated with Bisphosphonate-Induced osteonecrosis of the jaw: an Exome-Wide association analysis. J Bone Miner Res. 2018;33(1):91–98. doi:10.1002/jbmr.32854.
   PubMed Web of Science ®Google Scholar
• Abed É, Delalandre A, Lajeunesse D. Beneficial effect of resveratrol on phenotypic features and activity of osteoarthritic osteoblasts. Arthritis Res Ther. 2017;19(1):151. doi:10.1186/s13075-017-1365-26.
   PubMedGoogle Scholar
• Louvet L, Leterme D, Delplace S, et al. Sirtuin 1 deficiency decreases bone mass and increases bone marrow adiposity in a mouse model of chronic energy deficiency. Bone. 2020;136:115361. doi:10.1016/j.bone.2020.115361.9.
   PubMed Web of Science ®Google Scholar
• Domazetovic V, Marcucci G, Falsetti I, et al. Blueberry juice. Antioxidants protect osteogenic activity against oxidative stress and improve long-term activation of the mineralization process in human osteoblast-like SaOS-2 cells: involvement of SIRT1. Antioxidants (Basel). 2020;9(2):125. doi:10.3390/antiox9020125.9.
   PubMedGoogle Scholar
• Kim KM, Wagle S, Moon YJ, et al. Interferon β protects against avascular osteonecrosis through interleukin 6 inhibition and silent information regulator transcript-1 upregulation. Oncotarget. 2017;9(3):3562–3575. doi:10.18632/oncotarget.233376.
   PubMedGoogle Scholar
• Matsuda Y, Minagawa T, Okui T, et al. Resveratrol suppresses the alveolar bone resorption induced by artificial trauma from occlusion in mice. Oral Dis. 2018;24(3):412–421. doi:10.1111/odi.12785.
   PubMed Web of Science ®Google Scholar
• Sugatani T, Agapova O, Malluche HH, et al. SIRT6 deficiency culminates in low-turnover osteopenia. Bone. 2015;81:168–177. doi:10.1016/j.bone.2015.07.0180.
   PubMed Web of Science ®Google Scholar
• Fei Y, Shimizu E, McBurney MW, et al. Sirtuin 1 is a negative regulator of parathyroid hormone stimulation of matrix metalloproteinase 13 expression in osteoblastic cells: role of sirtuin 1 in the action of PTH on osteoblasts. J Biol Chem. 2015;290(13):8373–8382. doi:10.1074/jbc.M114.6027635.
   PubMed Web of Science ®Google Scholar
• Liu L, Gu H, Liu H, et al. Protective effect of resveratrol against IL-1β-induced inflammatory response on human osteoarthritic chondrocytes partly via the TLR4/MyD88/NF-κB signaling pathway: an "in vitro study". Int J Mol Sci. 2014;15(4):6925–6940. doi:10.3390/ijms150469253.
   PubMed Web of Science ®Google Scholar
• Kim HS, Vassilopoulos A, Wang RH, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20(4):487–499. doi:10.1016/j.ccr.2011.09.0044.
   PubMed Web of Science ®Google Scholar
• Beirowski B, Gustin J, Armour SM, et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci U S A. 2011;108(43):E952–961. doi:10.1073/pnas.1104969108.0.
   PubMed Web of Science ®Google Scholar
• Jing Y, Zhou Y, Zhou F, et al. SIRT2 deficiency prevents age-related bone loss in rats by inhibiting osteoclastogenesis. Cell Mol Biol (Noisy-le-Grand). 2019;65(7):66–71. doi:10.14715/cmb/2019.65.7.120.
   PubMed Web of Science ®Google Scholar
• Guo Z, He E, Wang D, et al. Targeting a novel liver-bone communication by SIRT2 for osteoporosis treatment. Preprint. 2022.
   Google Scholar
• Bellizzi D, Rose G, Cavalcante P, et al. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics. 2005;85(2):258–263. doi:10.1016/j.ygeno.2004.11.0034.
   PubMed Web of Science ®Google Scholar
• Rose G, Dato S, Altomare K, et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol. 2003;38(10):1065–1070. doi:10.1016/s0531-5565(03)00209-29.
   PubMed Web of Science ®Google Scholar
• Lombard DB, Alt FW, Cheng HL, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27(24):8807–8814. doi:10.1128/MCB.01636-071.
   PubMed Web of Science ®Google Scholar
• McDonnell E, Peterson BS, Bomze HM, et al. SIRT3 regulates progression and development of diseases of aging. Trends Endocrinol Metab. 2015;26(9):486–492. doi:10.1016/j.tem.2015.06.0017.
   PubMed Web of Science ®Google Scholar
• van de Ven RAH, Santos D, Haigis MC. Mitochondrial sirtuins and molecular mechanisms of aging. Trends Mol Med. 2017;23(4):320–331. doi:10.1016/j.molmed.2017.02.0056.
   PubMed Web of Science ®Google Scholar
• Gao J, Feng Z, Wang X, et al. SIRT3/SOD2 maintains osteoblast differentiation and bone formation by regulating mitochondrial stress. Cell Death Differ. 2018;25(2):229–240. doi:10.1038/cdd.2017.1442.
   PubMed Web of Science ®Google Scholar
• Huh JE, Shin JH, Jang ES, et al. Sirtuin 3 (SIRT3) maintains bone homeostasis by regulating AMPK-PGC-1β axis in mice. Sci Rep. 2016;6(1):22511. doi:10.1038/srep225115.
   PubMedGoogle Scholar
• Ho L, Wang L, Roth TM, et al. Sirtuin-3 promotes adipogenesis, osteoclastogenesis, and bone loss in aging male mice. Endocrinol. 2017;158(9):2741–2753. doi:10.1210/en.2016-17391.
   PubMed Web of Science ®Google Scholar
• Chen Y, Fu LL, Wen X, et al. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis. 2014;5(2):e1047–e1047. doi:10.1038/cddis.2014.149.
   PubMedGoogle Scholar
• Tseng AH, Shieh SS, Wang DL. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med. 2013;63:222–234. doi:10.1016/j.freeradbiomed.2013.05.0026.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang J, Deng X, et al. Advances in characterization of SIRT3 deacetylation targets in mitochondrial function. Biochimie. 2020;179:1–13. doi:10.1016/j.biochi.2020.08.0217.
   PubMed Web of Science ®Google Scholar
• Rahman M, Nirala NK, Singh A, et al. Drosophila Sirt2/mammalian SIRT3 deacetylates ATP synthase β and regulates complex V activity. J Cell Biol. 2014;206(2):289–305. doi:10.1083/jcb.2014041184.
   PubMed Web of Science ®Google Scholar
• Vassilopoulos A, Pennington JD, Andresson T, et al. SIRT3 deacetylates ATP synthase F1 complex proteins in response to nutrient- and exercise-induced stress. Antioxid Redox Signal. 2014;21(4):551–564. doi:10.1089/ars.2013.5420.0.
   PubMed Web of Science ®Google Scholar
• Hirschey MD, Shimazu T, Capra JA, et al. SIRT1 and SIRT3 deacetylate homologous substrates: aceCS1,2 and HMGCS1,2. Aging (Albany NY). 2011;3(6):635–642. doi:10.18632/aging.1003397.
   PubMedGoogle Scholar
• Finley LW, Haas W, Desquiret-Dumas V, et al. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PLoS One. 2011;6(8):e23295. doi:10.1371/journal.pone.0023295.
   PubMed Web of Science ®Google Scholar
• Nogueiras R, Habegger KM, Chaudhary N, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012;92(3):1479–1514. doi:10.1152/physrev.00022.20111.
   PubMed Web of Science ®Google Scholar
• Ahn BH, Kim HS, Song S, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A. 2008;105(38):14447–14452. doi:10.1073/pnas.08037901051.
   PubMed Web of Science ®Google Scholar
• Shi T, Wang F, Stieren E, et al. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005;280(14):13560–13567. doi:10.1074/jbc.M4146702000.
   PubMed Web of Science ®Google Scholar
• Sundaresan NR, Gupta M, Kim G, et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009;119(9):2758–2771. doi:10.1172/JCI391621.
   PubMed Web of Science ®Google Scholar
• Xie X, Wang L, Zhao B, et al. SIRT3 mediates decrease of oxidative damage and prevention of ageing in porcine fetal fibroblasts. Life Sci. 2017;177:41–48. doi:10.1016/j.lfs.2017.01.010.
   PubMed Web of Science ®Google Scholar
• He J, Liu X, Su C, et al. Inhibition of mitochondrial oxidative damage improves reendothelialization capacity of endothelial progenitor cells via SIRT3 (sirtuin 3)-enhanced SOD2 (superoxide dismutase 2) deacetylation in hypertension. Arterioscler Thromb Vasc Biol. 2019;39(8):1682–1698. doi:10.1161/ATVBAHA.119.3126133.
   PubMed Web of Science ®Google Scholar
• Ploumi C, Daskalaki I, Tavernarakis N. Mitochondrial biogenesis and clearance: a balancing act. FEBS J. 2017;284(2):183–195. doi:10.1111/febs.138201.
   PubMed Web of Science ®Google Scholar
• Wang S, Deng Z, Ma Y, et al. The role of autophagy and mitophagy in bone metabolic disorders. Int J Biol Sci. 2020;16(14):2675–2691. doi:10.7150/ijbs.466274.
   PubMed Web of Science ®Google Scholar
• Li Y, Ma Y, Song L, et al. SIRT3 deficiency exacerbates p53/parkin-mediated mitophagy inhibition and promotes mitochondrial dysfunction: implication for aged hearts. Int J Mol Med. 2018;41(6):3517–3526. doi:10.3892/ijmm.2018.35556.
   PubMed Web of Science ®Google Scholar
• Yu W, Gao B, Li N, et al. Sirt3 deficiency exacerbates diabetic cardiac dysfunction: role of Foxo3A-parkin-mediated mitophagy. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):1973–1983. doi:10.1016/j.bbadis.2016.10.0218.
   PubMed Web of Science ®Google Scholar
• Qiao A, Wang K, Yuan Y, et al. Sirt3-mediated mitophagy protects tumor cells against apoptosis under hypoxia. Oncotarget. 2016;7(28):43390–43400. doi:10.18632/oncotarget.97178.
   PubMedGoogle Scholar
• He Y, Wu Z, Xu L, et al. The role of SIRT3-mediated mitochondrial homeostasis in osteoarthritis. Cell Mol Life Sci. 2020;77(19):3729–3743. doi:10.1007/s00018-020-03497-94.
   PubMed Web of Science ®Google Scholar
• Rached MT, Kode A, Xu L, et al. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab. 2010;11(2):147–160. doi:10.1016/j.cmet.2010.01.001.2.
   PubMed Web of Science ®Google Scholar
• Li Y, Yu C, Shen G, et al. Sirt3-MnSOD axis represses nicotine-induced mitochondrial oxidative stress and mtDNA damage in osteoblasts. Acta Biochim Biophys Sin. 2015;47(4):306–312. doi:10.1093/abbs/gmv013. Epub 2015 Mar 10.3.
   Google Scholar
• ]Ding Y, Yang H, Wang Y, et al. Sirtuin 3 is required for osteogenic differentiation through maintenance of PGC-1ɑ-SOD2-mediated regulation of mitochondrial function. Int J Biol Sci. 2017;13(2):254–264. doi:10.7150/ijbs.170537.
   PubMed Web of Science ®Google Scholar
• Tautzenberger A, Kovtun A, Ignatius A. Nanoparticles and their potential for application in bone. Int J Nanomedicine. 2012;7:4545–4557. doi:10.2147/IJN.S341272.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang Y, Ba T, et al. Genotoxic evaluation of titanium dioxide nanoparticles in vivo and in vitro. Toxicol Lett. 2014;226(3):314–319. doi:10.1016/j.toxlet.2014.02.0207.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang J, Lin T, et al. Excessive production of mitochondrion-derived reactive oxygen species induced by titanium ions leads to autophagic cell death of osteoblasts via the SIRT3/SOD2 pathway. Mol Med Rep. 2020;22(1):257–264. doi:10.3892/mmr.2020.110946.
   PubMed Web of Science ®Google Scholar
• Niska K, Pyszka K, Tukaj C, et al. Titanium dioxide nanoparticles enhance production of superoxide anion and alter the antioxidant system in human osteoblast cells. Int J Nanomedicine. 2015;10:1095–1107. doi:10.2147/IJN.S735574.
   PubMed Web of Science ®Google Scholar
• Zheng K, Bai J, Li N, et al. Protective effects of sirtuin 3 on titanium particle-induced osteogenic inhibition by regulating the NLRP3 inflammasome via the GSK-3β/β-catenin signalling pathway. Bioact Mater. 2021;6(10):3343–3357. doi:10.1016/j.bioactmat.2021.02.0395.
   PubMed Web of Science ®Google Scholar
• Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115–137. doi:10.1210/edrv.21.2.03951.
   PubMed Web of Science ®Google Scholar
• Farr JN, Almeida M. The spectrum of fundamental basic science discoveries contributing to organismal aging. J Bone Miner Res. 2018;33(9):1568–1584. doi:10.1002/jbmr.35641.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee YD, Kim HJ, et al. SOD2 and Sirt3 control osteoclastogenesis by regulating mitochondrial ROS. J Bone Miner Res. 2017;32(2):397–406. doi:10.1002/jbmr.29744.
   PubMed Web of Science ®Google Scholar
• Wang F, Guo J, Wang S, et al. B‐cell lymphoma‐3 controls mesenchymal stem cell commitment and senescence during skeletal aging. Clin Transl Med. 2022;12(7):e955. doi:10.1002/ctm2.9553.
   PubMed Web of Science ®Google Scholar
• Almeida M, Laurent MR, Dubois V, et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev. 2017;97(1):135–187. doi:10.1152/physrev.00033.20152.
   PubMed Web of Science ®Google Scholar
• Richardson KK, Ling W, Krager K, et al. Ionizing radiation activates mitochondrial function in osteoclasts and causes bone loss in young adult male mice. Int J Mol Sci. 2022;23(2):675. doi:10.3390/ijms23020675.9.
   PubMed Web of Science ®Google Scholar
• Li N, Li X, Zheng K, et al. Inhibition of sirtuin 3 prevents titanium particle-induced bone resorption and osteoclastsogenesis via suppressing ERK and JNK signaling. Int J Biol Sci. 2021;17(5):1382–1394. doi:10.7150/ijbs.539923.
   PubMed Web of Science ®Google Scholar
• K Kanfi Y, Shalman R, Peshti V, et al. Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett. 2008;582(5):543–548. doi:10.1016/j.febslet.2008.01.0195.
   PubMed Web of Science ®Google Scholar
• Kugel S, Mostoslavsky R. Chromatin and beyond: the multitasking roles for SIRT6. Trends Biochem Sci. 2014;39(2):72–81. doi:10.1016/j.tibs.2013.12.0026.
   PubMed Web of Science ®Google Scholar
• Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006;124(2):315–329. doi:10.1016/j.cell.2005.11.0446.
   PubMed Web of Science ®Google Scholar
• Mu W, Wang Z, Ma C, et al. Metformin promotes the proliferation and differentiation of murine preosteoblast by regulating the expression of sirt6 and oct4. Pharmacol Res. 2018;129:462–474. doi:10.1016/j.phrs.2017.11.0208.
   PubMed Web of Science ®Google Scholar
• Zhang DM, Cui DX, Xu RS, et al. Phenotypic research on senile osteoporosis caused by SIRT6 deficiency. Int J Oral Sci. 2016;8(2):84–92. doi:10.1038/ijos.2015.570.
   PubMed Web of Science ®Google Scholar
• Zhang D, Jing J, Lou F, et al. Evidence for excessive osteoclast activation in SIRT6 null mice. Sci Rep. 2018;8(1):10992. doi:10.1038/s41598-018-28716-z3.
   PubMedGoogle Scholar
• Kim SJ, Piao Y, Lee MG, et al. Loss of sirtuin 6 in osteoblast lineage cells activates osteoclasts, resulting in osteopenia. Bone. 2020;138:115497. doi:10.1016/j.bone.2020.1154971.
   PubMed Web of Science ®Google Scholar
• Park SJ, Huh JE, Shin J, et al. Sirt6 cooperates with Blimp1 to positively regulate osteoclast differentiation. Sci Rep. 2016;6(1):26186. doi:10.1038/srep261869.
   PubMedGoogle Scholar
• Moon YJ, Zhang Z, Bang IH, et al. Sirtuin 6 in preosteoclasts suppresses age- and estrogen deficiency-related bone loss by stabilizing estrogen receptor α. Cell Death Differ. 2019;26(11):2358–2370. doi:10.1038/s41418-019-0306-91.
   PubMed Web of Science ®Google Scholar
• Kok SH, Hou KL, Hong CY, et al. Sirtuin 6 modulates hypoxia-induced apoptosis in osteoblasts via inhibition of glycolysis: implication for pathogenesis of periapical lesions. J Endod. 2015;41(10):1631–1637. doi:10.1016/j.joen.2015.05.0086.
   PubMed Web of Science ®Google Scholar
• Li L, Shi L, Yang S, et al. SIRT7 is a histone desuccinylase that functionally links to chromatin compaction and genome stability. Nat Commun. 2016;7(1):12235. doi:10.1038/ncomms122359.
   PubMedGoogle Scholar
• Paredes S, Chua KF. SIRT7 clears the way for DNA repair. Embo J. 2016;35(14):1483–1485. doi:10.15252/embj.201694904.
   PubMed Web of Science ®Google Scholar
• Tang M, Li Z, Zhang C, et al. SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA damage repair. Sci Adv. 2019;5(3):eaav1118. doi:10.1126/sciadv.aav11184.
   PubMed Web of Science ®Google Scholar
• Chang HHY, Pannunzio NR, Adachi N, et al. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18(8):495–506. doi:10.1038/nrm.2017.481.
   PubMed Web of Science ®Google Scholar
• Vazquez BN, Thackray JK, Simonet NG, et al. SIRT7 promotes genome integrity and modulates non-homologous end joining DNA repair. Embo J. 2016;35(14):1488–1503. doi:10.15252/embj.2015934992.
   PubMed Web of Science ®Google Scholar
• Ryu D, Jo YS, Lo Sasso G, et al. A SIRT7-dependent acetylation switch of GABPβ1 controls mitochondrial function. Cell Metab. 2014;20(5):856–869. doi:10.1016/j.cmet.2014.08.0013.
   PubMed Web of Science ®Google Scholar
• Shin J, He M, Liu Y, et al. SIRT7 represses myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep. 2013;5(3):654–665. doi:10.1016/j.celrep.2013.10.0070.
   PubMed Web of Science ®Google Scholar
• Vakhrusheva O, Smolka C, Gajawada P, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res. 2008;102(6):703–710. doi:10.1161/CIRCRESAHA.107.1645588.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Yoshizawa T, Karim MF, et al. SIRT7 has a critical role in bone formation by regulating lysine acylation of SP7/osterix. Nat Commun. 2018;9(1):2833. doi:10.1038/s41467-018-05187-45.
   PubMedGoogle Scholar
• Tseng PC, Hou SM, Chen RJ, et al. Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res. 2011;26(10):2552–2563. doi:10.1002/jbmr.4605.
   PubMed Web of Science ®Google Scholar
• Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429(6993):771–776. doi:10.1038/nature025831.
   PubMed Web of Science ®Google Scholar
• Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD + metabolism and SIRT1 activity. Nature. 2009;458(7241):1056–1060. doi:10.1038/nature078138.
   PubMed Web of Science ®Google Scholar
• Yao H, Yao Z, Zhang S, et al. Upregulation of SIRT1 inhibits H2O2-induced osteoblast apoptosis via FoxO1/β-catenin pathway. Mol Med Rep. 2018;17(5):6681–6690. doi:10.3892/mmr.2018.86576.
   PubMed Web of Science ®Google Scholar
• Gu X, Wang Z, Gao J, et al. SIRT1 suppresses p53-dependent apoptosis by modulation of p21 in osteoblast-like MC3T3-E1 cells exposed to fluoride. Toxicol in Vitro. 2019;57:28–38. doi:10.1016/j.tiv.2019.02.0067.
   PubMed Web of Science ®Google Scholar
• Huang W, Shang WL, Wang HD, et al. Sirt1 overexpression protects murine osteoblasts against TNF-α-induced injury in vitro by suppressing the NF-κB signaling pathway. Acta Pharmacol Sin. 2012;33(5):668–674. doi:10.1038/aps.2011.1893.
   PubMed Web of Science ®Google Scholar
• Ishii KA, Fumoto T, Iwai K, et al. Coordination of PGC-1β and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med. 2009;15(3):259–266. doi:10.1038/nm.1910.
   PubMed Web of Science ®Google Scholar
• Scherz-Shouval R, Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci. 2011;36(1):30–38. doi:10.1016/j.tibs.2010.07.0072.
   PubMed Web of Science ®Google Scholar
• Sun H, Wu Y, Fu D, et al. SIRT6 regulates osteogenic differentiation of rat bone marrow mesenchymal stem cells partially via suppressing the nuclear factor-κB signaling pathway. Stem Cells. 2014;32(7):1943–1955. doi:10.1002/stem.16717.
   PubMed Web of Science ®Google Scholar
• Xiao F, Zhou Y, Liu Y, et al. Inhibitory effect of Sirtuin6 (SIRT6) on osteogenic differentiation of bone marrow mesenchymal stem cells. Med Sci Monit. 2019;25:8412–8421. doi:10.12659/MSM.9171180.
   PubMed Web of Science ®Google Scholar
• Chen EEM, Zhang W, Ye CCY, et al. Knockdown of SIRT7 enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells partly via activation of the wnt/β-catenin signaling pathway. Cell Death Dis. 2017;8(9):e3042–e3042. doi:10.1038/cddis.2017.4294.
   PubMedGoogle Scholar
• Fonseca-Santos B, Chorilli M. The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems. Int J Pharm. 2020;589:119832. doi:10.1016/j.ijpharm.2020.1198320.
   PubMedGoogle Scholar
• Du S, Shen S, Ding S, et al. Suppression of microRNA-323-3p restrains vascular endothelial cell apoptosis via promoting sirtuin-1 expression in coronary heart disease. Life Sci. 2021;270:119065. doi:10.1016/j.lfs.2021.1190651.
   PubMed Web of Science ®Google Scholar
• Chao CC, Huang CL, Cheng JJ, et al. SRT1720 as an SIRT1 activator for alleviating paraquat-induced models of Parkinson’s disease. Redox Biol. 2022;58:102534. doi:10.1016/j.redox.2022.1025340.
   PubMed Web of Science ®Google Scholar
• Hua R, Wang GZ, Shen QW, et al. Sleeve gastrectomy ameliorated high-fat diet (HFD)-induced non-alcoholic fatty liver disease and upregulated the nicotinamide adenine dinucleotide +/sirtuin-1 pathway in mice. Asian J Surg. 2021;44(1):213–220. doi:10.1016/j.asjsur.2020.05.0305.
   PubMed Web of Science ®Google Scholar
• Hao L, Park J, Jang HY, et al. Inhibiting protein kinase activity of pyruvate kinase M2 by SIRT2 deacetylase attenuates psoriasis. J Invest Dermatol. 2021;141(2):355–363.e6. doi:10.1016/j.jid.2020.06.0247.
   PubMed Web of Science ®Google Scholar
• Park S, Chung MJ, Son JY, et al. The role of sirtuin 2 in sustaining functional integrity of the liver. Life Sci. 2021;285:119997. doi:10.1016/j.lfs.2021.1199978.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin C, Yang Q, et al. Spinal sirtuin 3 contributes to electroacupuncture analgesia in mice with chronic constriction Injury-Induced neuropathic pain. Neuromodulation. 2023;26(3):563–576. doi:10.1016/j.neurom.2022.07.0094.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ren J, Wang F, et al. Chinese herbal medicine alleviates the pathogenesis of polycystic ovary syndrome by improving oxidative stress and glucose metabolism via mitochondrial sirtuin 3 signaling. Phytomedicine. 2023;109:154556. doi:10.1016/j.phymed.2022.1545569.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang B, Yang W, et al. Sirtuin 3 relieves inflammatory responses elicited by lipopolysaccharide via the PGC1α-NFκB pathway in bovine mammary epithelial cells. J Dairy Sci. 2023;106(2):1315–1329. doi:10.3168/jds.2022-221143.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang L, Hua F, et al. FOXM1-activated SIRT4 inhibits NF-κB signaling and NLRP3 inflammasome to alleviate kidney injury and podocyte pyroptosis in diabetic nephropathy. Exp Cell Res. 2021;408(2):112863. doi:10.1016/j.yexcr.2021.112863. PD: 34626587
   PubMed Web of Science ®Google Scholar
• He L, Wang J, Yang Y, et al. SIRT4 suppresses doxorubicin-induced cardiotoxicity by regulating the AKT/mTOR/autophagy pathway. Toxicol. 2022;469:153119. doi:10.1016/j.tox.2022.1531193.
   PubMed Web of Science ®Google Scholar
• Zheng D, Qiwen Zeng, He D et al. SIRT5 alleviates hepatic ischemia and reperfusion injury by diminishing oxidative stress and inflammation via elevating SOD1 and IDH2 expression. Exp Cell Res 2022;419(2):113319. doi:10.1016/j.yexcr.2022.1133196.
   PubMed Web of Science ®Google Scholar
• He T, Shang J, Gao C, et al. A novel SIRT6 activator ameliorates neuroinflammation and ischemic brain injury via EZH2/FOXC1 axis. Acta Pharm Sin B. 2021;11(3):708–726. doi:10.1016/j.apsb.2020.11.0027.
   PubMed Web of Science ®Google Scholar
• Bian C, Zhang R, Wang Y, et al. Sirtuin 6 affects glucose reabsorption and gluconeogenesis in type 1 diabetes via FoxO1. Mol Cell Endocrinol. 2022;547:111597. doi:10.1016/j.mce.2022.1115978.
   PubMed Web of Science ®Google Scholar
• Wang D, Wei X, Chen X, et al. GRIM-19 inhibits proliferation and induces apoptosis in a p53-dependent manner in colorectal cancer cells through the SIRT7/PCAF/MDM2 axis. Exp Cell Res. 2021;407(1):112799. doi:10.1016/j.yexcr.2021.1127990.
   PubMed Web of Science ®Google Scholar
• Li XT, Song JW, Zhang ZZ, et al. Sirtuin 7 mitigates renal ferroptosis, fibrosis and injury in hypertensive mice by facilitating the KLF15/Nrf2 signaling. Free Radic Biol Med. 2022;193(Pt 1):459–473. doi:10.1016/j.freeradbiomed.2022.10.3206.
   PubMedGoogle Scholar
• Meccariello R, D'Angelo S. Impact of polyphenolic-food on longevity: an elixir of life. An overview. Antioxidants (Basel). 2021;10(4):507. doi:10.3390/antiox100405072.
   PubMedGoogle Scholar
• Ziętara P, Dziewięcka M, Augustyniak M. Why is longevity still a scientific mystery? Sirtuins-past, present and future. Int J Mol Sci. 2022;24(1):728. doi:10.3390/ijms240107281.
   PubMed Web of Science ®Google Scholar
• Cao M, Zhao Q, Sun X, et al. Sirtuin 3: emerging therapeutic target for cardiovascular diseases. Free Radic Biol Med. 2022;180:63–74. doi:10.1016/j.freeradbiomed.2022.01.005.
   PubMed Web of Science ®Google Scholar
• He Y, Huang W, Zhang C, et al. Energy metabolism disorders and potential therapeutic drugs in heart failure. Acta Pharm Sin B. 2021;11(5):1098–1116. doi:10.1016/j.apsb.2020.10.0072.
   PubMed Web of Science ®Google Scholar
• Zaganjor E, Yoon H, Spinelli JB, et al. SIRT4 is an early regulator of branched-chain amino acid catabolism that promotes adipogenesis. Cell Rep. 2021;36(2):109345. doi:10.1016/j.celrep.2021.1093453.
   PubMed Web of Science ®Google Scholar
• Yudoh K, Yui N, Terauchi K, et al. Sirtuins in bone and cartilage biology. In: Sirtuin biology in medicine. New York: Academic Press; 2021. p. 341–351. doi:10.1016/C2016-0-04428-5.
   Google Scholar
• Dai Y, Lin J, Ren J, et al. NAD + metabolism in peripheral neuropathic pain. Neurochem Int. 2022;161:105435. doi:10.1016/j.neuint.2022.1054356.
   PubMed Web of Science ®Google Scholar
• He L, Wang J, Yang Y, et al. Mitochondrial sirtuins in parkinson’s disease. Neurochem Res. 2022;47(6):1491–1502. doi:10.1007/s11064-022-03560-w2.
   PubMed Web of Science ®Google Scholar
• Govindarajulu M, Ramesh S, Neel L, et al. Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer’s disease. Neurochem Int. 2021;144:104958. doi:10.1016/j.neuint.2021.1049585.
   PubMed Web of Science ®Google Scholar
• Julien C, Tremblay C, Emond V, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol. 2009;68(1):48–58. doi:10.1097/NEN.0b013e31819223486.
   PubMed Web of Science ®Google Scholar
• Mohamad Nasir NF, Zainuddin A, Shamsuddin S. Emerging roles of sirtuin 6 in Alzheimer’s disease. J Mol Neurosci. 2018;64(2):157–161. doi:10.1007/s12031-017-1005-y2.
   PubMed Web of Science ®Google Scholar
• Kumar V, Kundu S, Singh A, et al. Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective. Curr Neuropharmacol. 2022;20(1):158–178. doi:10.2174/1570159X196662106091600174.
   PubMed Web of Science ®Google Scholar
• Yu Z, Fan D, Gui B, et al. Neurodegeneration-associated TDP-43 interacts with fragile X mental retardation protein (FMRP)/staufen (STAU1) and regulates SIRT1 expression in neuronal cells. J Biol Chem. 2012;287(27):22560–22572. doi:10.1074/jbc.M112.357582.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu R, Zhang W, et al. Role of SIRT1 in HIV-associated kidney disease. Am J Physiol Renal Physiol. 2020;319(2):F335–F344. doi:10.1152/ajprenal.00140.20207.
   PubMed Web of Science ®Google Scholar
• Ji J, Wang K, Meng X, et al. Elaiophylin inhibits tumorigenesis of human lung adenocarcinoma by inhibiting mitophagy via suppression of SIRT1/Nrf2 signaling. Cancers (Basel). 2022;14(23):5812. doi:10.3390/cancers142358124.
   PubMed Web of Science ®Google Scholar
• Mahjabeen I, Rizwan M, Fareen G, et al. Mitochondrial sirtuins genetic variations and gastric cancer risk: evidence from retrospective observational study. Gene. 2022;807:145951. doi:10.1016/j.gene.2021.1459511.
   PubMed Web of Science ®Google Scholar
• Palomer X, Aguilar-Recarte D, García R, et al. Sirtuins: to be or not to be in diabetic cardiomyopathy. Trends Mol Med. 2021;27(6):554–571. doi:10.1016/j.molmed.2021.03.0044.
   PubMed Web of Science ®Google Scholar
• Hu J, Pan LY, Li Y, et al. Deacetylation-activated construction of single quantum dot-based nanosensor for sirtuin 1 assay. Talanta. 2021;224:121918. doi:10.1016/j.talanta.2020.1219189.
   PubMed Web of Science ®Google Scholar
• Kratz EM, Kokot I, Dymicka-Piekarska V, et al. Sirtuins-the new important players in women’s gynecological health. Antioxidants. 2021;10(1):84. doi:10.3390/antiox100100847.
   Web of Science ®Google Scholar
• Bartosch C, Monteiro-Reis S, Almeida-Rios D, et al. Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium. Oncotarget. 2016;7(2):1144–1154. doi:10.18632/oncotarget.6691.
   PubMedGoogle Scholar
• Xu D, He H, Jiang X, et al. SIRT2 plays a novel role on progesterone, estradiol and testosterone synthesis via PPARs/LXRα pathways in bovine ovarian granular cells. J Steroid Biochem Mol Biol. 2019;185:27–38. doi:10.1016/j.jsbmb.2018.07.0051.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ren J, Wang F, et al. Mitochondrial and glucose metabolic dysfunctions in granulosa cells induce impaired oocytes of polycystic ovary syndrome through sirtuin 3. Free Radic Biol Med. 2022;187:1–16. doi:10.1016/j.freeradbiomed.2022.05.0100.
   PubMed Web of Science ®Google Scholar
• Fernando KKM, Wijayasinghe YS. Sirtuins as potential therapeutic targets for mitigating neuroinflammation associated with Alzheimer’s disease. Front Cell Neurosci. 2021;15:746631. doi:10.3389/fncel.2021.7466314.
   PubMed Web of Science ®Google Scholar
• Mourits VP, Helder LS, Matzaraki V, et al. The role of sirtuin 1 on the induction of trained immunity. Cell Immunol. 2021;366:104393. doi:10.1016/j.cellimm.2021.1043931.
   PubMed Web of Science ®Google Scholar
• Winnik S, Auwerx J, Sinclair DA, et al. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J. 2015;36(48):3404–3412. doi:10.1093/eurheartj/ehv2909.
   PubMed Web of Science ®Google Scholar
• Balaiya S, Khetpal V, Chalam KV. Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor activation in choroidal endothelial cells through hypoxia inducible factor-2α. Mol Vis. 2012;18:114–120.2
   PubMed Web of Science ®Google Scholar
• Thandapilly SJ, Wojciechowski P, Behbahani J, et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens. 2010;23(2):192–196. doi:10.1038/ajh.2009.2281.
   PubMed Web of Science ®Google Scholar
• Ozawa H, Miyagawa S, Fukushima S, et al. Sirtuin1 regulates the stem cell therapeutic effects on regenerative capability for treating severe heart failure in a juvnile animal model. Ann Thorac Surg. 2016;102(3):803–812. doi:10.1016/j.athoracsur.2016.02.0935.
   PubMed Web of Science ®Google Scholar
• Sundaresan NR, Vasudevan P, Zhong L, et al. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-jun. Nat Med. 2012;18(11):1643–1650. doi:10.1038/nm.2961.
   PubMed Web of Science ®Google Scholar
• Matsushima S, Sadoshima J. The role of sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol. 2015;309(9):H1375–89. doi:10.1152/ajpheart.00053.20152.
   PubMed Web of Science ®Google Scholar
• Araki S, Izumiya Y, Rokutanda T, et al. Sirt7 contributes to myocardial tissue repair by maintaining transforming growth factor-β signaling pathway. Circulation. 2015;132(12):1081–1093. doi:10.1161/CIRCULATIONAHA.114.0148210.
   PubMed Web of Science ®Google Scholar
• Sidorova-Darmos E, Wither RG, Shulyakova N, et al. Differential expression of sirtuin family members in the developing, adult, and aged rat brain. Front Aging Neurosci. 2014;6:333. doi:10.3389/fnagi.2014.003336.
   PubMed Web of Science ®Google Scholar
• Ramadori G, Lee CE, Bookout AL, et al. Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci. 2008;28(40):9989–9996. doi:10.1523/JNEUROSCI.3257-08.20086.
   PubMed Web of Science ®Google Scholar
• Glorioso C, Oh S, Douillard GG, et al. Brain molecular aging, promotion of neurological disease and modulation by Sirtuin5 longevity gene polymorphism. Neurobiol Dis. 2011;41(2):279–290. doi:10.1016/j.nbd.2010.09.016.
   PubMed Web of Science ®Google Scholar
• Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med. 2013;5(3):344–352. doi:10.1002/emmm.2013024512.
   PubMed Web of Science ®Google Scholar
• Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron. 2014;81(3):471–483. doi:10.1016/j.neuron.2014.01.0286.
   PubMed Web of Science ®Google Scholar
• Jiang DQ, Wang Y, Li MX, et al. SIRT3 in neural stem cells attenuates microglia activation-induced oxidative stress injury through mitochondrial pathway. Front Cell Neurosci. 2017;11:7. doi:10.3389/fncel.2017.000079.
   PubMed Web of Science ®Google Scholar
• Li L, Sun Q, Li Y, et al. Overexpression of SIRT1 induced by resveratrol and inhibitor of miR-204 suppresses activation and proliferation of microglia. J Mol Neurosci. 2015;56(4):858–867. doi:10.1007/s12031-015-0526-54.
   PubMed Web of Science ®Google Scholar
• Pais TF, Szegő ÉM, Marques O, et al. The NAD‐dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. Embo J. 2013;32(19):2603–2616. doi:10.1038/emboj.2013.200.
   PubMed Web of Science ®Google Scholar
• Etchegaray JP, Chavez L, Huang Y, et al. The histone deacetylase SIRT6 controls embryonic stem cell fate via TET-mediated production of 5-hydroxymethylcytosine. Nat Cell Biol. 2015;17(5):545–557. doi:10.1038/ncb3147.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Yamashita T. Sirtuins in neuroendocrine regulation and neurological diseases. Front Neurosci. 2018;12:778. doi:10.3389/fnins.2018.007785.
   PubMed Web of Science ®Google Scholar
• Szegő ÉM, Outeiro TF, Kazantsev AG. Sirtuins in brain and neurodegenerative disease. In: Introductory review on sirtuins in biology, aging, and disease. New York: Academic Press; 2018. p. 175–195.
   Google Scholar
• Zhang F, Wang S, Gan L, et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol. 2011;95(3):373–395. doi:10.1016/j.pneurobio.2011.09.0012.
   PubMed Web of Science ®Google Scholar
• Roth M, Chen WY. Sorting out functions of sirtuins in cancer. Oncogene. 2014;33(13):1609–1620. doi:10.1038/onc.2013.1200.
   PubMed Web of Science ®Google Scholar
• Morris BJ. Seven sirtuins for seven deadly diseases ofaging. Free Radic Biol Med. 2013;56:133–171. doi:10.1016/j.freeradbiomed.2012.10.525.
   PubMed Web of Science ®Google Scholar
• Jeong SM, Haigis MC. Sirtuins in cancer: a balancing act between genome stability and metabolism. Mol Cells. 2015;38(9):750–758. doi:10.14348/molcells.2015.01674.
   PubMed Web of Science ®Google Scholar
• Liu PY, Xu N, Malyukova A, et al. The histone deacetylase SIRT2 stabilizes myc oncoproteins. Cell Death Differ. 2013;20(3):503–514. doi:10.1038/cdd.2012.1478.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zou SW, Liu Y, et al. Lysine-5 acetylation negatively regulates lactate dehydrogenase a and is decreased in pancreatic cancer. Cancer Cell. 2013;23(4):464–476. 15doi: 10.1016/j.ccr.2013.02.0053.
   PubMed Web of Science ®Google Scholar
• Cui Y, Qin L, Wu J, et al. SIRT3 enhances glycolysis and proliferation in SIRT3-Expressing gastric cancer cells. PLoS One. 2015;10(6):e0129834. doi:10.1371/journal.pone.01298341.
   PubMed Web of Science ®Google Scholar
• Finley LW, Carracedo A, Lee J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell. 2011;19(3):416–428. doi:10.1016/j.ccr.2011.02.0143.
   PubMed Web of Science ®Google Scholar
• He S, He C, Yuan H, et al. The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients. Cell Physiol Biochem. 2014;34(6):2061–2069. doi:10.1159/0003664014.
   PubMedGoogle Scholar
• Yu FY, Xu Q, Wu DD, et al. The prognostic and clinicopathological roles of sirtuin-3 in various cancers. PLoS One. 2016;11(8):e0159801. doi:10.1371/journal.pone.01598012.
   PubMed Web of Science ®Google Scholar
• Jeong SM, Xiao C, Finley LW, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013;23(4):450–463. doi:10.1016/j.ccr.2013.02.0241.
   PubMed Web of Science ®Google Scholar
• Sebastián C, Zwaans BM, Silberman DM, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 2012;151(6):1185–1199. doi:10.1016/j.cell.2012.10.0476.
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen P, Huang Z, et al. Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep. 2015;5(1):9787. doi:10.1038/srep097871.
   PubMedGoogle Scholar
• Geng Q, Peng H, Chen F, et al. High expression of Sirt7 served as a predictor of adverse outcome in breast cancer. Int J Clin Exp Pathol. 2015;8(2):1938–1945.
   PubMed Web of Science ®Google Scholar
• Wang HL, Lu RQ, Xie SH, et al. SIRT7 exhibits oncogenic potential in human ovarian cancer cells. Asian Pac J Cancer Prev. 2015;16(8):3573–3577. doi:10.7314/apjcp.2015.16.8.35730.
   PubMedGoogle Scholar
• Wang RH, Kim HS, Xiao C, et al. Hepatic Sirt1 deficiency in mice impairs mTorc2/akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest. 2011;121(11):4477–4490. doi:10.1172/JCI46243.
   PubMed Web of Science ®Google Scholar
• Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem. 2005;280(21):20589–20595. doi:10.1074/jbc.M4123572002.
   PubMed Web of Science ®Google Scholar
• Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423(6939):550–555. doi:10.1038/nature01667.
   PubMed Web of Science ®Google Scholar
• Xiong X, Tao R, DePinho RA, et al. Deletion of hepatic FoxO1/3/4 genes in mice significantly impacts on glucose metabolism through downregulation of gluconeogenesis and upregulation of glycolysis. PLoS One. 2013;8(8):e74340. doi:10.1371/journal.pone.00743408.
   PubMed Web of Science ®Google Scholar
• Zhang W, Patil S, Chauhan B, et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem. 2006;281(15):10105–10117. doi:10.1074/jbc.M6002722005.
   PubMed Web of Science ®Google Scholar
• Jiang W, Wang S, Xiao M, et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell. 2011;43(1):33–44. doi:10.1016/j.molcel.2011.04.0288.
   PubMed Web of Science ®Google Scholar
• Liu Y, Dentin R, Chen D, et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature. 2008;456(7219):269–273. doi:10.1038/nature073499.
   PubMed Web of Science ®Google Scholar
• Kim HS, Xiao C, Wang RH, et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 2010;12(3):224–236. S doi: 10.1016/j.cmet.2010.06.0099.
   PubMed Web of Science ®Google Scholar
• Yoshizawa T, Karim MF, Sato Y, et al. SIRT7 controls hepatic lipid metabolism by regulating the ubiquitin-proteasome pathway. Cell Metab. 2014;19(4):712–721. doi:10.1016/j.cmet.2014.03.0062.
   PubMed Web of Science ®Google Scholar
• He Y, Luo Y, Zhang D, et al. PGK1-mediated cancer progression and drug resistance. Am J Cancer Res. 2019;9(11):2280–2302.5.
   PubMed Web of Science ®Google Scholar
• Hu H, Zhu W, Qin J, et al. Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology. 2017;65(2):515–528. doi:10.1002/hep.288879.
   PubMed Web of Science ®Google Scholar
• Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327–338. doi:10.1016/j.cmet.2009.02.0064.
   PubMed Web of Science ®Google Scholar
• Zhou M, Luo J, Zhang H. Role of sirtuin 1 in the pathogenesis of ocular disease (review). Int J Mol Med. 2018;42(1):13–20. doi:10.3892/ijmm.2018.36233.
   PubMed Web of Science ®Google Scholar
• Elhanati S, Kanfi Y, Varvak A, et al. Multiple regulatory layers of SREBP1/2 by SIRT6. Cell Rep. 2013;4(5):905–912. doi:10.1016/j.celrep.2013.08.0068.
   PubMed Web of Science ®Google Scholar
• Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121–125. doi:10.1038/nature087781.
   PubMed Web of Science ®Google Scholar
• Fennell L, Dumenil T, Wockner L, et al. Integrative genome-scale DNA methylation analysis of a large and unselected cohort reveals 5 distinct subtypes of colorectal adenocarcinomas. Cell Mol Gastroenterol Hepatol. 2019;8(2):269–290. doi:10.1016/j.jcmgh.2019.04.0022.
   PubMed Web of Science ®Google Scholar
• Laurent G, German NJ, Saha AK, et al. SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol Cell. 2013;50(5):686–698. doi:10.1016/j.molcel.2013.05.0122.
   PubMed Web of Science ®Google Scholar
• Kang HS, Okamoto K, Kim YS, et al. Nuclear orphan receptor TAK1/TR4-deficient mice are protected against obesity-linked inflammation, hepatic steatosis, and insulin resistance. Diabetes. 2011;60(1):177–188. doi:10.2337/db10-06284.
   PubMed Web of Science ®Google Scholar
• Ren JH, Tao Y, Zhang ZZ, et al. Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1. J Virol. 2014;88(5):2442–2451. doi:10.1128/JVI.02861-13.
   PubMed Web of Science ®Google Scholar
• Deng JJ, Kong KY, Gao WW, et al. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. Biochim Biophys Acta Gene Regul Mech. 2017;1860(4):491–501. doi:10.1016/j.bbagrm.2017.02.007.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu Y, Xue J, et al. MicroRNA-141 targets Sirt1 and inhibits autophagy to reduce HBV replication. Cell Physiol Biochem. 2017;41(1):310–322. doi:10.1159/0004561623.
   PubMedGoogle Scholar
• Li WY, Ren JH, Tao NN, et al. The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo. Arch Virol. 2016;161(3):621–630. doi:10.1007/s00705-015-2712-82.
   PubMed Web of Science ®Google Scholar
• Ligat G, Goto K, Verrier E, et al. Targeting viral cccDNA for cure of chronic hepatitis B. Curr Hepatol Rep. 2020;19(3):235–244. doi:10.1007/s11901-020-00534-w.
   PubMedGoogle Scholar
• Jiang H, Cheng ST, Ren JH, et al. SIRT6 inhibitor, OSS_128167 restricts hepatitis B virus transcription and replication through targeting transcription factor peroxisome proliferator-activated receptors α. Front Pharmacol. 2019;10:1270. doi:10.3389/fphar.2019.012709.
   PubMed Web of Science ®Google Scholar
• Qi C, Mao X, Zhang Z, et al. Classification and differential diagnosis of diabetic nephropathy. J Diabetes Res. 2017;2017:8637138–8637137. doi:10.1155/2017/86371385.
   PubMed Web of Science ®Google Scholar
• Tang J, Yao D, Yan H, et al. The role of microRNAs in the pathogenesis of diabetic nephropathy. Int J Endocrinol. 2019;2019:8719060–8719068. doi:10.1155/2019/87190603.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao L, Xing Y, et al. Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression. Biomed Pharmacother. 2018;108:7–14. doi:10.1016/j.biopha.2018.09.0070.
   PubMed Web of Science ®Google Scholar
• Wang T, Zhu H, Yang S, et al. Let-7a-5p may participate in the pathogenesis of diabetic nephropathy through targeting HMGA2. Mol Med Rep. 2019;19(5):4229–4237. doi:10.3892/mmr.2019.100574.
   PubMed Web of Science ®Google Scholar
• Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021;2021:1497449–1497417. doi:10.1155/2021/14974490.
   PubMed Web of Science ®Google Scholar
• Guedes M, Pecoits-Filho R. Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist’s point of view. J Intern Med. 2022;291(2):165–180. doi:10.1111/joim.134242.
   PubMed Web of Science ®Google Scholar
• Mortuza R, Chen S, Feng B, et al. High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS One. 2013;8(1):e54514. doi:10.1371/journal.pone.00545143.
   PubMed Web of Science ®Google Scholar
• Wax MB, Camras CB, Fiscella RG, et al. Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol. 2002;133 Suppl(6):S1–S10. doi:10.1016/s0002-9394(02)01459-97.
   PubMedGoogle Scholar
• Balaiya S, Ferguson LR, Chalam KV. Evaluation of sirtuin role in neuroprotection of retinal ganglion cells in hypoxia. Invest Ophthalmol Vis Sci. 2012;53(7):4315–4322. doi:10.1167/iovs.11-92596.
   PubMed Web of Science ®Google Scholar
• Dioum EM, Chen R, Alexander MS, et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science. 2009;324(5932):1289–1293. doi:10.1126/science.11699562.
   PubMed Web of Science ®Google Scholar
• Lim JH, Lee YM, Chun YS, et al. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell. 2010;38(6):864–878. doi:10.1016/j.molcel.2010.05.0236.
   PubMed Web of Science ®Google Scholar
• Levkovitch-Verbin H, Quigley HA, Martin KR, et al. The transcription factor c-jun is activated in retinal ganglion cells in experimental rat glaucoma. Exp Eye Res. 2004;80(5):663–670. doi:10.1016/j.exer.2004.11.0163.
   Web of Science ®Google Scholar
• Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta. 2010;1804(8):1684–1689. doi:10.1016/j.bbapap.2010.05.0023.
   PubMed Web of Science ®Google Scholar
• Bien A, Seidenbecher CI, Böckers TM, et al. Apoptotic versus necrotic characteristics of retinal ganglion cell death after partial optic nerve injury. J Neurotrauma. 1999;16(2):153–163. doi:10.1089/neu.1999.16.153.
   PubMed Web of Science ®Google Scholar
• Mesner PW, Epting CL, Hegarty JL, et al. A timetable of events during programmed cell death induced by trophic factor withdrawal from neuronal PC12 cells. J Neurosci. 1995;15(11):7357–7366. doi:10.1523/JNEUROSCI.15-11-07357.1995.
   PubMed Web of Science ®Google Scholar
• Yang X, Cai J, Powell DW, et al. Up-regulation of sirtuins in the glaucomatous human retina. Investig Ophthalmol Vis Sci. 2014;55(13):2398.
   Web of Science ®Google Scholar